Q-Pan H1N1 vaccine

The Q-Pan H1N1 vaccine is a monovalent, inactivated, split-virion pandemic influenza vaccine developed by GSK Biologicals. It is based on the A/California/7/2009 (H1N1)v-like viral antigen and is formulated with GSK's proprietary AS03 adjuvant system, an oil-in-water emulsion containing squalene and alpha-tocopherol. The inclusion of AS03 allows for significant antigen-sparing, achieving high immunogenicity with a lower dose of hemagglutinin (HA) protein compared to unadjuvanted vaccines. The vaccine was developed in response to the 2009 H1N1 pandemic and has been evaluated in clinical trials across various age groups, including children and adolescents, to assess safety and the induction of protective antibody responses against the viral HA protein.

Brand names

PandemrixArepanrix

Other names

A/California/7/2009 (H1N1)v-like influenza vaccineGSK H1N1 pandemic vaccineadjuvanted pandemic H1N1 vaccine